Lion's Mane & Trametes: Supportive Oncology Treatment

Lion's mane and Trametes Versicolor are two of the most studied medicinal mushrooms in supportive oncology, with polysaccharide compounds shown to enhance natural killer cell activity, modulate immune response during chemotherapy, and reduce common treatment side effects in preclinical and clinical research.

Lion's mane (Hericium erinaceus) and Trametes Versicolor, also known as turkey tail, have been used in East Asian medicine for centuries. Modern oncology research has taken a specific interest in both — not as standalone cures, but as supportive agents that may help the immune system withstand the stress of conventional cancer treatment.

What Makes These Two Mushrooms Relevant in Oncology Support

Both mushrooms produce beta-glucan polysaccharides that interact with immune cell receptors, but their research profiles differ. Trametes Versicolor has one of the deepest clinical research histories of any medicinal mushroom, largely because its extract PSK (brand name Krestin) received drug approval in Japan in 1977 and in China in 1987 (Wasser, Appl Microbiol Biotechnol, 2002, PMID 12242575). Lion's mane has a smaller but growing body of oncology-adjacent research, more focused on immune support, appetite, and general treatment tolerance than on the pharmaceutical-grade survival data available for PSK.

Lion's Mane: Immune Support and Cell-Level Research

Laboratory studies on Hericium erinaceus extracts have reported the ability to induce apoptosis, or programmed cell death, in certain cancer cell lines, along with anti-inflammatory activity that may help offset the chronic inflammation associated with tumor growth and chemotherapy recovery (Patel and Goyal, 3 Biotech, 2012, PMID 28324347). Much of this evidence comes from cell-culture and animal models rather than large human trials, so lion's mane is best understood today as a general immune and wellness support during cancer treatment rather than a mushroom with its own approved oncology drug, the way Trametes Versicolor's PSK is.

Trametes Versicolor and PSK: Decades of Clinical Use in Asia

PSK and a related compound, PSP (polysaccharide-peptide), are the most clinically developed compounds from Trametes Versicolor. Across more than three decades of Asian research, these compounds have been studied as adjuvant therapy in gastric, esophageal, nasopharyngeal, colorectal, and lung cancers, generally used alongside — never in place of — chemotherapy or surgery (Zhong et al., Front Pharmacol, 2019). A Phase 1 clinical trial in American women with breast cancer found that Trametes Versicolor extract was well tolerated and produced measurable immune activation, providing an early safety and dosing foundation for further Western research (Torkelson et al., ISRN Oncol, 2012, PMID 23251833). An earlier trial from the same research group similarly reported improved immune cell counts in breast cancer patients taking Trametes Versicolor during radiation therapy (Standish et al., J Soc Integr Oncol, 2008, PMID 18761292).

How These Compounds Modulate the Immune System

The immunological activity of PSK and PSP appears to work through an agonistic effect on Toll-like receptors, particularly TLR2 and TLR4 (Lu et al., Clin Cancer Res, 2011). TLRs are membrane proteins found on dendritic cells and macrophages — immune cells that are typically first to detect an antigen. When triggered, they release pro-inflammatory cytokines and activate downstream T- and B-lymphocyte responses. This mechanism helps explain why Trametes Versicolor extracts are studied specifically for their ability to support, rather than directly replace, the body's own anticancer immune defenses during treatment.

Supporting Patients Through Chemotherapy and Radiation

One consistent theme across the research on both mushrooms is a focus on treatment tolerance rather than tumor size alone. Extracts have been studied for their potential to reduce fatigue, support appetite, and help maintain the bone marrow's capacity to produce healthy blood cells during chemotherapy cycles. Radiation therapy commonly causes lymphopenia and reduced natural killer cell activity; some research suggests Trametes Versicolor extract may help improve immune status in patients undergoing radiation specifically because of this immunosuppressive side effect (Torkelson et al., ISRN Oncol, 2012, PMID 23251833). Supporting a patient's ability to complete a planned treatment course on schedule, without dose reductions or delays caused by low blood counts or exhaustion, is itself considered a clinically meaningful outcome — separate from any direct antitumor effect.

Cancer Types Studied With Mushroom Extracts

The research base for Trametes Versicolor and, to a lesser extent, lion's mane spans a range of cancer types, though evidence depth varies considerably by diagnosis. Gastric and colorectal cancer have the strongest evidence, largely from decades of Japanese and Chinese trials of pharmaceutical-grade PSK used alongside chemotherapy. Other cancers studied in the literature include esophageal, nasopharyngeal, and lung cancer, along with early cell-line research in breast cancer, cervical cancer (HeLa cell line), acute promyelocytic leukemia (HL-60 and NB-4 cell lines), and Burkitt's lymphoma (Raji cell line). It's worth being precise about what this means in practice: cell-line findings show biological activity worth studying further, they do not establish that a supplement will produce the same effect in a person. The clinical, human-trial evidence is concentrated almost entirely in gastric and colorectal cancer.

Choosing a Quality Extract

Not all lion's mane or Trametes Versicolor products are equivalent, and this matters more in an oncology context than almost anywhere else. Look for extracts that state their polysaccharide or beta-glucan content, specify hot-water or dual extraction (the method that pulls polysaccharides out of the fungal cell wall), and identify the mushroom part used — fruiting body extracts generally carry a stronger research pedigree than mycelium-on-grain products. Third-party testing for contaminants and heavy metals is worth checking for as well, since mushrooms can bioaccumulate them from their growing substrate. None of this replaces the pharmaceutical-grade PSK used in Japanese clinical trials, but it does help ensure a supplement is at least consistent with the type of extract the research describes.

Safety, Tolerability, and Working With Your Oncology Team

Across the available studies, extracts of both mushrooms have generally been well tolerated, which is part of why they continue to be studied as adjuncts rather than dismissed outright. That said, because both mushrooms modulate immune activity, anyone considering them during cancer treatment should discuss timing, dosing, and lab monitoring with their oncology team first. This matters even more for patients with autoimmune conditions, organ transplant history, or those on immunosuppressive medication, where immune-modulating supplements carry a different risk profile than in an otherwise healthy patient. Bringing a simple written summary — product name, dose, and schedule — to oncology appointments is one of the most effective ways to avoid interaction oversight.

Bottom Line

Lion's mane and Trametes Versicolor open a genuine, evidence-backed avenue for supportive cancer care, particularly around immune modulation, treatment tolerance, and quality of life. Trametes Versicolor's PSK carries the deepest clinical track record of the two, including decades of approved use in Japan alongside chemotherapy. Lion's mane's evidence is earlier-stage but complementary, with a stronger focus on general immune and inflammatory support. Neither replaces surgery, chemotherapy, or radiation — both work best as a coordinated part of a patient's overall oncology care plan, never as a substitute for it.

You can also find these mushrooms in our store:

1. Lion's mane fruits
2. Lion's mane capsules
3. Lion's mane extract
4. Trametes Versicolor fruits
5. Trametes Versicolor extract

Frequently Asked Questions

What is Lion's mane?

Lion's mane (Hericium erinaceus) is a functional mushroom studied for its immune-modulating and neuroregenerative properties, with early oncology research focused on apoptosis induction and anti-inflammatory activity in cancer cell lines.

Is Trametes Versicolor an approved cancer treatment?

Purified PSK (Krestin), derived from Trametes Versicolor, is an approved adjunct chemotherapy drug in Japan for certain cancers, used alongside — never instead of — standard treatment. It is not approved as a standalone cancer treatment anywhere, and over-the-counter turkey tail supplements are not the same regulated pharmaceutical product.

Can I take these mushrooms during chemotherapy or radiation?

Only with your oncology team's explicit involvement. Because both mushrooms modulate immune activity, they can interact with treatment timing and lab monitoring. Discuss any product you're considering at your next appointment rather than adding it independently.

How do you use Lion's mane and Trametes Versicolor?

Both are commonly available as extracts, tinctures, capsules, or dried fruiting bodies. The right form depends on your health goals, tolerance, and your oncology team's guidance during active treatment.

Are Lion's mane and Trametes Versicolor safe?

Both are generally considered safe for healthy adults at recommended doses, but anyone with a cancer diagnosis, autoimmune condition, or on immunosuppressive medication should consult their treating physician first, given their immune-modulating activity.

Related Articles

• Trametes in Adjunct Oncology: Survival and Quality of Life
• Trametes Versicolor: PSK/PSP Immune Guide
• Mushroom Supplements: A Complete Guide

Sources

1. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002. PMID 12242575
2. Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics. 3 Biotech. 2012. PMID 28324347
3. Torkelson CJ, et al. Phase 1 clinical trial of Trametes Versicolor in women with breast cancer. ISRN Oncol. 2012. PMID 23251833
4. Standish LJ, et al. Trametes versicolor mushroom immune therapy in breast cancer. J Soc Integr Oncol. 2008. PMID 18761292